| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Bz-Try-pNA targets chymotrypsin, a serine protease. Chymotrypsin hydrolyzes peptide bonds with aromatic or large hydrophobic side chains. Bz-Try-pNA is a substrate for chymotrypsin, not an inhibitor.
|
|---|---|
| ln Vitro |
Bz-Try-pNA is used as a substrate to measure chymotrypsin activity in vitro. Chymotrypsin cleaves the peptide bond in Bz-Try-pNA, releasing p-nitroaniline. The release of p-nitroaniline is monitored spectrophotometrically.
|
| ln Vivo |
In vivo activity data for Bz-Try-pNA are not relevant, as the compound is a substrate used in in vitro enzyme assays. It is not used as a therapeutic agent.
|
| Enzyme Assay |
The in vitro enzyme assay for Bz-Try-pNA involves measuring its cleavage by chymotrypsin. Chymotrypsin is incubated with Bz-Try-pNA at various concentrations. The release of p-nitroaniline is monitored spectrophotometrically at 405 nm. The enzyme activity is calculated from the initial rate of the reaction.
|
| Cell Assay |
In vitro cellular assays are not typically performed with Bz-Try-pNA, as the compound is a substrate used in cell-free enzyme assays.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with Bz-Try-pNA, as the compound is a substrate used in in vitro enzyme assays.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Bz-Try-pNA are not relevant, as the compound is not used as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for Bz-Try-pNA are not extensively available, as the compound is used as a research reagent. Standard safety assessments for research chemicals have likely been performed.
|
| References | |
| Additional Infomation |
Benzoyltyrosine 4-nitroanilide is the (L)-isomer
N-Benzoyl-L-tyrosine p-nitroanilide (Bz-Try-pNA) is a chromogenic substrate for chymotrypsin. It is used in biochemical assays to measure chymotrypsin activity. The compound has a CAS number of 6154-45-6. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C22H19N3O5
|
|---|---|
| Molecular Weight |
405.40
|
| Exact Mass |
405.132
|
| CAS # |
6154-45-6
|
| PubChem CID |
188992
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.373 g/cm3
|
| Boiling Point |
776.8ºC at 760 mmHg
|
| Melting Point |
235-237 °C
|
| Flash Point |
423.6ºC
|
| Index of Refraction |
1.677
|
| LogP |
4.267
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC=1C=CC(=CC1)C[C@@H](C(NC2=CC=C([N+]([O-])=O)C=C2)=O)NC(C3=CC=CC=C3)=O
|
| InChi Key |
CJERUMAUMMIPRF-FQEVSTJZSA-N
|
| InChi Code |
InChI=1S/C22H19N3O5/c26-19-12-6-15(7-13-19)14-20(24-21(27)16-4-2-1-3-5-16)22(28)23-17-8-10-18(11-9-17)25(29)30/h1-13,20,26H,14H2,(H,23,28)(H,24,27)/t20-/m0/s1
|
| Chemical Name |
N-[(2S)-3-(4-hydroxyphenyl)-1-(4-nitroanilino)-1-oxopropan-2-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4667 mL | 12.3335 mL | 24.6670 mL | |
| 5 mM | 0.4933 mL | 2.4667 mL | 4.9334 mL | |
| 10 mM | 0.2467 mL | 1.2333 mL | 2.4667 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
